August 16th 2024
Justin M. Watts, MD, discusses the final 5-year results of the 2102-HEM-101 trial of olutasidenib in patients with IDH1-mutated acute myeloid leukemia.
July 24th 2024
Justin M. Watts, MD, discusses the design and purpose of a phase 1 trial evaluating INCB057643 in myelofibrosis and other advanced myeloid neoplasms.
June 11th 2024
Justin M. Watts, MD, discusses the safety profile and tolerability of INCB057643 in patients with myelofibrosis.